Watchlist

Watchlist
Amphastar Pharmaceuticals, Inc. (AMPH)
Amphastar Pharmaceuticals, Inc. (AMPH)
Does Amphastar's Pipeline Warrant Its Valuation?
In early 2017 , I was particularly bearish on shares of specialty generics maker Amphastar ( AMPH ). I thought shares would decline significantly throughout 2017, and it looked my prediction was on-track until the company received a product approval in September and shares gradually drifted t…
Your Daily Pharma Scoop: Gilead's Potential, Celgene CAR-T Candidate, Cellectar Soars
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day ea…
Your Daily Pharma Scoop: Dynavax Beyond Heplisav-B, Novartis' Cosentyx, Shire Granted ODD
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Dynavax Today we will focus on an article on Dynavax…
Amphastar Pharmaceuticals (AMPH) Presents At PiperJaffray 29th Annual Healthcare Conference - Slideshow
The following slide deck was published by Amphastar in conjunction with this Read more …
Cost of U.S. opioid epidemic tops $500B
In an analysis to be released today, the White House will say the true cost of the opioid drug epidemic in 2015 was $504B, more than six times larger than the most recent estimate. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Industries Limited, Health…
Your Daily Pharma Scoop: Neurocrine Has Upside, Dynavax Gets FDA Nod, Sage Soars
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Neurocrine Biosciences Today we will d…
Premarket analyst action - healthcare
Nektar Therapeutics (NASDAQ: NKTR ) initiated with Buy rating and $35 (16% upside) price target by Canaccord Genuity. More news on: Nektar Therapeutics, AnaptysBio, Acorda Therapeutics, Inc., Healthcare stocks news, Read more …
Amphastar Pharmaceuticals' (AMPH) Management on Q3 2017 Results - Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2017 Earnings Conference Call November 08, 2017 17:00 P.M. ET Executives Jason B. Shandell - President Bill Peters - CFO, SVP, and Treasurer Analysts Elliot Wilbur - Raymond James David Maris - Wells Fargo David Amsellem - Piper J…
Amphastar reports Q3 results
Amphastar (NASDAQ: AMPH ): Q3 EPS of $0.07 Revenue of $57.92M (-9.8% Y/Y) Press Release More news on: Amphastar, Earnings news and commentary, Healthcare stocks news,
Notable earnings after Wednesday's close
AEZS , AFSI , AKAO , ALB , ALDW , ALRM , AMBC , AMPH , AMRS , ANDV , ANDX , ANGI , APU , ATHX , ATO , BKCC , BLDR , BREW , BRS , BW , CAPR , CASC , CBAY , CDTX , CHEF , CLNS , CODI , COGT , COLL , CPA , CSOD , CTL , CTRE , CXW , DK , DKL , DOX , ECR , …
Mylan leads generic drug maker selloff on expanded Fed probe into generic drug pricing; shares down 8%
Some generic drug makers are under pressure in apparent response the federal government's decision to expand its investigation into alleged collusion to fix drug prices. More news on: Mylan Inc, Amphastar, ANI Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more…
Amphastar Pharmaceuticals, Inc. (AMPH)
Amphastar Pharmaceuticals, Inc. (AMPH)